World Prematurity Day

The 17th of November is World Prematurity Day. Let's spotlight the resilience of premature babies [...]

SIME begins clinical trial validating point-of-care device that rapidly predicts neonatal respiratory disease at birth in the NICU

The FAST 2 (Fourier-transform Infrared Spectroscopy guided Surfactant Therapy) trial begins in 4 Danish University [...]

SIME AI device that predicts acute respiratory disease receives CE Mark – changing the standard of care for millions of babies worldwide

The point-of-care device, which predicts severe lung disease in the ICU and NICU, has been CE [...]

SIME strengthens board to prepare for commercialisation

Morten Henneveld, a life science executive with decades of commercial and operations experience, joins SIME [...]

Early prediction of newborn Chronic Lung Disease is urgently needed for effective treatment

Global neonatal key opinion leaders conclude that prediction of CLD at birth may prevent or [...]

SIME Announces Publication of Clinical Study Demonstrating Reduced Pulmonary Surfactant in COVID-19 ARDS patients

First of its kind diagnostic for measuring surfactant in multifactorial Acute Respiratory Distress Syndrome (ARDS) [...]

SIME awarded US Patent covering the method of the company’s novel neonatal diagnostic platform

LONDON, May 13, 2020 – SIME Clinical AI, a pioneer in applying AI and data [...]

Why are there less premature births during lockdowns?

Since record began, the number of babies born premature (before 37 weeks’ gestation) has increased [...]

Press release: SIME Clinical AI Further Expands IP Portfolio with IOT and Cloud Diagnostic Platform Patent in Europe

LONDON, Nov. 11, 2020 /PRNewswire/ — SIME Clinical AI today announced that the European Patent Office intends [...]

SIME Clinical AI Platform could enable early targeted treatment in critically ill COVID-19 patients

A recent peer reviewed letter to editor by SIME has been published in Critical Care [...]